David L. Chan
A5037936050- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Colorectal and Anal Carcinomas
- Inflammatory Biomarkers in Disease Prognosis
- Genetic factors in colorectal cancer
- Medical Imaging Techniques and Applications
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Radiopharmaceutical Chemistry and Applications
- Advanced Breast Cancer Therapies
- PI3K/AKT/mTOR signaling in cancer
- Gastrointestinal Tumor Research and Treatment
- Mobile and Web Applications
- Cancer, Lipids, and Metabolism
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Glioma Diagnosis and Treatment
- Pancreatitis Pathology and Treatment
- Metastasis and carcinoma case studies
Royal North Shore Hospital
2016-2025
The University of Sydney
2015-2025
University Health Network
2024-2025
Toronto General Hospital
2025
Princess Margaret Cancer Centre
2016-2024
Northern Sydney Local Health District
2016-2023
Northern Cancer Institute
2019-2023
University of Illinois Chicago
2021-2023
Sunnybrook Health Science Centre
2016-2022
Health Sciences Centre
2016-2022
Abstract The Kaiser Permanente (KP) Research Program on Genes, Environment and Health (RPGEH), in collaboration with the University of California—San Francisco, undertook genome-wide genotyping >100,000 subjects that constitute Genetic Epidemiology Adult Aging (GERA) cohort. project, which generated >70 billion genotypes, represents first large-scale use Affymetrix Axiom Genotyping Solution. Because took place over a short 14-month period, creating near-real-time analysis...
neoMONARCH assessed the biological effects of abemaciclib in combination with anastrozole neoadjuvant setting.Postmenopausal women stage I-IIIB HR+/HER2- breast cancer were randomized to a 2-week lead-in abemaciclib, anastrozole, or plus followed by 14 weeks combination. The primary objective evaluated change Ki67 from baseline 2 treatment. Additional objectives included clinical, radiologic, and pathologic responses, safety, as well gene expression changes related cell proliferation immune...
Gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) are heterogeneous in clinical course, biology, and outcomes. The NETPET score predicts survival by scoring uptake on dual [68Ga]DOTATATE [18F]FDG PET/CT scans. We aimed to validate previous single-centre findings a multicentre, international study.Dual scans were assigned of P1 (DOTATATE positive/FDG negative), P2-4 positive), or P5 negative/FDG positive). score, histological grade, age at diagnosis, presence/absence extrahepatic...
Pancreatic cancer has poor survival despite modern-day advances in its management. At present, there are no available biomarkers that can predict chemotherapy response or help inform prognosis. In more recent years, been increased interest potential inflammatory biomarkers, with studies revealing a worse prognosis of patients higher neutrophil-to-lymphocyte ratio range tumour types. Our aim was to assess the role three peripheral blood predicting earlier disease treated neoadjuvant and as...
The aim of this study was to investigate the relationship between absorbed dose and response colorectal cancer liver metastases treated with [90Y]-resin microspheres explore possible clinical imaging derived prognostic factors. FDG PET/CT used measure individual lesions a measured dose, from post-treatment 90Y PET imaging. Predicted also planning [99mTc]-MAA SPECT data. Peak standardised uptake value total lesion glycolysis (TLG) were explored as measures, compared metrics including average...
PET scans using <sup>18</sup>F-FDG and somatostatin receptor imaging agents are both used in of neuroendocrine neoplasms (NENs). We have suggested the "NETPET score," uptake tracers, as a prognostic biomarker NENs. The name NETPET score was previously to capture score9s intent summarize information from dual tumors. demonstrated effectiveness gastroenteropancreatic NENs (GEPNENs). Its relevance bronchial remains undetermined. <b>Methods:</b> This is retrospective multicenter study...
Grade 3 gastroenteropancreatic neuroendocrine neoplasms (G3 GEPNENs) are often aggressive, and the optimal treatment is unclear for this subgroup of (NENs). Temozolomide (TEM)-based regimens have been increasingly used to treat grade 1-2 NENs, but their efficacy in G3 NENs remains undetermined. We aimed assess clinical TEM-containing advanced GEPNENs.
115 Background: Cetuximab has been shown to improve survival in patients with KRAS wildtype metastatic colorectal cancer. However, high rates of hypersensitivity reactions (HSRs) limit its use, HSR up 10-20%. A major driver cetuximab is from pre-formed antibody response galactose-1,3-alpha-galactose (alpha-gal). Evidence retrospective studies supports alpha-gal pre-screening this setting. We are the first report on impact prospective screening HSR. Methods: Records were reviewed across three...
Abstract Background Many patients with locally advanced gastro-oesophageal cancers are unable to complete adjuvant 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy, raising questions about its therapeutic utility. The aim of this study was examine whether pathological response neoadjuvant FLOT can guide use. Methods Patients non-metastatic adenocarcinoma who received underwent surgery from 1 January 2017 2022 43 hospitals across 12 countries were analysed....
Abstract Background The use of CDKN2A/B deletions in the current WHO CNS classification (5th edition, 2021), has led to some ambiguity patient management. Further clinical studies are required fully ascertain impact this cohort and their optimal To end, we conducted a multi-centre retrospective study patterns care survey explore real-world outcomes homozygously (HoD) heterozygously deleted (HeD) IDH mutant tumours. Methods Demographic data were compiled for patients with IDH-mutant...